Lung Cancer Treatment Surgery 2026: New Neo-Adjuvant Breakthroughs 

Utyando lonyango lomhlaza wamaphaphu ngo-2026 ludibanisa unyango oluphambili lwe-neo-adjuvant ukuphucula kakhulu iziphumo zesigulana phambi koqhaqho. Le ndlela idibanisa i-immunotherapy, iziyobisi ezijoliswe kuzo, kunye nechemotherapy ukunciphisa amathumba, ukuphelisa i-micro-metastases, kunye nokwandisa amathuba okususwa ngokupheleleyo kwethumba. Impumelelo yakutsha nje ibonisa ukuba unyango lwenkqubo yangaphambi kotyando ngoku lumgangatho wokhathalelo lwezigaba ezininzi zomhlaza wemiphunga weseli ongeyonxalenye encinci (NSCLC), eguqula iimeko ebezifudula zingasebenzi ukuba zibe zezilawulekayo ngotyando.

Ukuzivelela koTyando loNyango loMhlaza weLung ngo-2026

Imbonakalo yomhlaba ye utyando lonyango lomhlaza wemiphunga iye yatshintsha i-paradigm njengoko sihamba nge-2026. Ngokomlando, utyando lwaluhlala luyindlela yokuqala yokukhusela isifo sokuqala. Nangona kunjalo, ukuhlanganiswa kweerejimeni ezinamandla ze-neo-adjuvant ziye zachaza ngokutsha ifestile yotyando. Namhlanje, isigqibo sokusebenza sihlala silandelwa yinkqubo yonyango yenkqubo eyenzelwe ukwandisa ukusebenza kwenkqubo elandelayo.

Olu tshintsho luqhutywa yidatha yeklinikhi eyomeleleyo ebonisa ukuba ukunyanga isifo ngokwenkqubo phambi kokuba ulawulo lwendawo lukhokelela kumazinga angcono okuphila ixesha elide. Ugqaliselo luye lwasuka ekususeni nje amathumba abonakalayo ukuya ekuhoyeni indlela yokuziphatha ngokwebhayoloji yeeseli zomhlaza ngokwazo. Oogqirha botyando kunye nee-oncologists ngoku basebenza kumaqela adityanisiweyo adityanisiweyo amaninzi ukuze amisele elona xesha lifanelekileyo longenelelo.

Ngo-2026, inkcazo ye "resectable" iye yanda. Iithumba ebezikade zithathwa ngokuba zikhulu kakhulu okanye zisondele kakhulu kwizakhiwo ezibalulekileyo ngoku zinokuthotywa ngokufanelekileyo. Oku kuvumela iindlela zotyando ezingangeneleli kwaye zigcine izicubu zemiphunga ezisempilweni. I-synergy phakathi kwe-oncology yonyango kunye noqhaqho lwe-thoracic ayizange ibe namandla, inika ithemba elitsha kwizigulana ezinesifo esiphezulu sasekhaya.

Kutheni i-Neo-Adjuvant Therapy isemgangathweni ngoku

Ukwamkelwa konyango lwe-neo-adjuvant njengesandulela esisemgangathweni utyando lonyango lomhlaza wemiphunga isekelwe kwizinto eziliqela ezibalulekileyo. Okokuqala, ilungisa isifo se-micrometastatic kwangoko. Iiseli zomhlaza zihlala zisasazeka kwamanye amalungu omzimba ngaphambi kokuba kubonwe ithumba eliphambili. Ngokulawula unyango lwenkqubo kuqala, oogqirha banokujolisa ezi seli zifihliweyo ngoko nangoko.

Okwesibini, ibonelela ngovavanyo lwe-vivo sensitivity. Ukujonga indlela ithumba elincipha ngayo okanye eliphendula ngayo kumachiza athile phambi kotyando kunika oogqirha ulwazi olubalulekileyo. Ukuba i-tumor ayiphenduli, isicwangciso sonyango sinokuhlengahlengiswa ngaphambi kokwenza utyando olukhulu. Le ndlela yokujongana nomntu inciphisa umngcipheko wotyando olungeyomfuneko kwizigulana ezinokuzuza ngakumbi kunyango olulolunye.

Okwesithathu, unyango lwe-neo-adjuvant lunyusa izinga le-R0 yokubuyisela kwakhona. Ukutshatyalaliswa kwe-R0 kuthetha ukuba ugqirha ususa yonke i-tumor enemida ecacileyo, engashiyi isifo esincinci ngasemva. Izifundo ngo-2025 kunye no-2026 ziqinisekisile ukuba unyango lwangaphambi kotyando lonyusa kakhulu amathuba okufumana esi siphumo sisemgangathweni segolide, esinxibelelene ngokuthe ngqo namazinga asezantsi okuphinda.

Ukuphumelela kwi-Immunotherapy-Based Neo-Adjuvant Regimens

Enye yezona nkqubela zibalulekileyo kwi utyando lonyango lomhlaza wemiphunga Iiprothokholi kukudityaniswa kwe-immune checkpoint inhibitors ngaphambi kokusebenza. Ngokungafaniyo nechemotherapy yesiko, ebulala ngokuthe ngqo iiseli ezahlula-hlula ngokukhawuleza, unyango lwe-immunotherapy luxhobisa isigulana sokuzikhusela komzimba ukuba siqaphele kwaye sihlasele iiseli zomhlaza. Xa isetyenziswe ngaphambi kokuhlinzwa, esi sicwangciso sibonise iziphumo eziphawulekayo kumazinga okuphendula kwe-pathological.

Izilingo zeklinikhi eziboniswe ngasekupheleni kuka-2025 kunye nasekuqaleni kuka-2026 ziye zagxininisa ukusebenza kakuhle kokudibanisa i-PD-1 okanye i-PD-L1 inhibitors kunye ne-chemotherapy. Ezi ndibaniselwano zikhokelele kumazinga aphezulu eMpendulo yePathological Major (MPR) kunye nePathological Complete Response (pCR). Kwiimeko ezininzi, ii-pathologists azifumani iiseli zomhlaza ezisebenzayo kwizicubu ezisusiweyo ngexesha lotyando, into eyayinqabile kwiminyaka embalwa edlulileyo.

Inkqubo ibandakanya ukuthintela iiproteni ezinjenge-PD-L1 ezisetyenziselwa iiseli zomhlaza ukufihla kwiiseli ze-T. Ngokukhulula ezi ziqhoboshi, amajoni omzimba asebenza kakhulu ngokuchasene nethumba. Lo msebenzi usoloko uqhubeka emva kotyando, unikezela ngohlobo "lwememori ye-immunological" enceda ukukhusela ukuphindaphinda. Esi senzo sintlu-mbini sokucutha ithumba kwangaphambili kunye nokukhusela emva kokuhlinzwa kuyenza ilitye lembombo lokhathalelo lwangoku.

UTshintsho oluPhambili lweNkcukacha yokuQhuba iiNkcukacha

Idatha yakutshanje evela kwiinkomfa ezinkulu ze-oncology ziye zaqinisa indima ye-immunotherapy kwimeko ye-neo-adjuvant. Uphononongo olubandakanya ii-arhente ezifana ne-nivolumab kunye ne-relatlimab zibonise ukuba nokwenzeka kunye nokhuseleko. Izigulane ezifumana ezi zidibaniso ngaphambi kokuhlinzwa zibonise amazinga aphezulu okutshatyalaliswa ngempumelelo ngaphandle kokwanda kweengxaki zotyando.

Ngokukodwa, uphando lubonisa ukuba ukongeza i-LAG-3 inhibitors kwi-PD-1 blockade inokuphucula ngakumbi iimpendulo. Le ndlela ekujoliswe kuyo kaninzi ihlasela ithumba ngeendlela ezahlukeneyo zokuzikhusela. Isiphumo yimpendulo enzulu kwaye ehlala ixesha elide, evumela oogqirha botyando ukuba benze utyando oluncinci ngelixa begcina ukhuseleko lwe-oncological.

Ngaphaya koko, ixesha lolu nyango liye landiswa. Iiprothokholi zangoku zibandakanya imijikelezo emibini ukuya kwemine ye-immunochemotherapy ngaphambi kokuhlinzwa. Le festile yanele ukuphembelela ukuhlehla kwethumba ngelixa unqanda i-fibrosis egqithisileyo enokwenza kube nzima ukwahlukana. Ibhalansi phakathi kokusebenza kunye nokusebenza kotyando kulawulwa ngononophelo ngokusekelwe kubungqina bamva nje.

Unyango olujolisiweyo kuDriver-Mutation Positive Patients

Ngelixa i-immunotherapy ilawula indawo yezigulana ezininzi, ezo zineenguqu ezithile zokuqhuba zifuna indlela eyahlukileyo. Kubantu abane-EGFR, ALK, okanye ukuguqulwa kwe-ROS1, i-tyrosine kinase inhibitors ejoliswe kuyo (TKIs) iba yinto ebalulekileyo kwizicwangciso ze-neo-adjuvant. Izikhokelo ze-2026 zigxininisa iyeza elichanekileyo, liqinisekisa ukuba ichiza elifanelekileyo lifikelela kwisigulane esifanelekileyo ngaphambi kokuba bangene kwigumbi lokusebenza.

Kwi-NSCLC eguqulweyo ye-EGFR, i-TKI yesizukulwana sesithathu njenge-osimertinib iyavavanywa kwimeko yangaphambi kotyando. Idatha yangaphambili ibonisa ukuba ezi arhente zinokunciphisa ngokufanelekileyo izicubu kunye nokucacisa i-lymph nodes. Nangona kunjalo, amazinga okuphendula apheleleyo nge-TKIs kuphela anokwahluka kulawo abonwa nge-immunochemotherapy. Ke ngoko, izicwangciso ezidityanisiweyo ezibandakanya ii-TKIs kunye nechemotherapy okanye ukuhlanganiswa kwendawo ziphantsi kophando olunzulu.

Umceli mngeni ulele ekulinganiseni ukushwabana kwethumba okunzulu okubonelelwa zii-TKIs kunye nesidingo semida yotyando ecacileyo. Olunye uphononongo lubonisa ukuba ngelixa amathumba ancipha kakhulu, isifo esishiyekileyo sinokuqhubeka kwimeko yokulala. Ngenxa yoko, isigqibo sokuqhubekeka kuqhaqho emva konyango olujolisiweyo lwe-neo-adjuvant lufuna ukucinga ngononophelo kunye novavanyo lwemolekyuli.

Indima yoNyango oluManyanisiweyo lweNdawo

Ukongeza kwiziyobisi zenkqubo, unyango oludibeneyo lwendawo (LCT) lufumana i-traction njengenxalenye ye-neo-adjuvant okanye isicwangciso se-peri-operative. I-LCT ibandakanya ubuchule obufana nonyango lwemitha yemitha ye-stereotactic (SBRT) esetyenziswa kwiindawo ezithile phambi okanye ecaleni konyango lwenkqubo. Le ndlela "yengxubevange" ijolise ekwandiseni ulawulo lwasekhaya ngelixa ilawula umngcipheko wenkqubo.

Uphando oluthiwe thaca ngo-2026 lubonisa ukuba kwizigulane ezine-oligometastatic isifo, ukudibanisa unyango olujoliswe kuyo kunye ne-LCT kunokwandisa ubomi obungenankqubela phambili kakhulu. Xa kulandelwa utyando lwethumba lokuqala, le ndlela yemultimodal ibonelela ngonyango olunokubakho kwizigulana ebezithathwa njengezinganyangekiyo ngaphambili. Imele utshintsho ukusuka kukhathalelo lokudambisa ukuya kwinjongo yonyango kwiimeko eziphambili.

Oogqirha botyando kufuneka bazazi iimpembelelo zemitha yangaphambili kwiindiza zethishu. Nangona i-SBRT ichanekile, inokubangela ukuvuvukala kunye ne-fibrosis. Ukucwangciswa kwezinto ezininzi kubalulekile ukuze kuqinisekiswe ukuba indawo yokusasazeka ayibeki esichengeni ukhuseleko loqhaqho olulandelayo. Ulungelelwaniso phakathi kwee-oncologists kunye noogqirha botyando lwethoracic lubaluleke kakhulu kunangaphambili.

Ubuchwephesha boTyando kunye neNtuthuko eNcinci kancinane

Icandelo lotyando lwe utyando lonyango lomhlaza wemiphunga iye yavela kwakhona ngokuhambelana nonyango lwezonyango. Ukwamkelwa ngokubanzi kwe-Video-Assisted Thoracoscopic Surgery (VATS) kunye neenkqubo zokuncedisa i-robotic ziye zaguqula ukubuyiswa kwesigulane. Ngo-2026, obu buchule buhlasela kancinci ngowona mgangatho ukhethwayo kwiimeko ezininzi ezinokuphinda zihlaziywe, ngaphandle kokuba ugqirha wotyando unobuchwephesha obaneleyo.

Iinkqubo zeRobhothi zibonelela nge-dexterity ephuculweyo kunye nokubonwa kwe-3D, evumela ukuchithwa okuchanekileyo nakwiimeko ezinzima ze-anatomical. Oku kunenzuzo ngakumbi emva konyango lwe-neo-adjuvant, apho iinqwelomoya zethishu zinokutshintshwa kukuvuvukala okanye i-fibrosis. Ukukwazi ukuhamba ngolu tshintsho ngokukhuselekileyo kunciphisa izinga lokuguqulwa ukuze uvule i-thoracotomy, ukugcina izibonelelo zotyando oluncinci.

Ngaphezu koko, ubungakanani bokususwa kwe-resection buyalungiswa. I-Segmentectomies kunye ne-wedge resections ziye zanda ukwenziwa kumathumba amancinci, asecaleni, ngakumbi kwizigulana ezinogcino lwemiphunga. Unyango lwe-neo-adjuvant luhlala lucutha amathumba ukuya kubungakanani apho ezi nkqubo zokonga imiphunga ziye zibe nokwenzeka. Ukugcina ukusebenza kwemiphunga kubalulekile kumgangatho wobomi, ngakumbi kwizigulana ezindala okanye abo banezigulo ezifana neCOPD.

Ukubaluleka kweLymph Node Dissection

Kungakhathaliseki ukuba yeyiphi indlela yotyando, i-lymph node dissection ihlala iyinto engenakuxoxwa. utyando lonyango lomhlaza wemiphunga. Ukulinganisa okuchanekileyo kuxhomekeke ekususweni nasekuhlalutyweni kwe-lymph nodes mediastinal. Unyango lwe-neo-adjuvant lunokuphelisa ii-lymph nodes, luzenze zibonakale ziqhelekileyo kwi-imaging, kodwa uvavanyo lwe-pathological lusafuneka ukuze kuqinisekiswe impendulo.

Izikhokelo ngo-2026 zigunyazisa ukuchithwa kwe-nodal okucwangcisiweyo kulo lonke utyando olunenjongo yonyango. Oku kuqinisekisa ukuba nasiphi na isifo esishiyekileyo sisusiwe kwaye sinikezela ngedatha echanekileyo kwizigqibo zonyango lwe-adjuvant. Ukutsiba eli nyathelo kunokukhokelela ekulandeleni kunye nokunakekelwa okungafanelekanga. Injongo ihlala i-R0 resection, ebandakanya ukucocwa kwazo zonke izitishi ze-nodal ezibandakanyekayo.

Inkcazo yesampulu ye-lymph node eyaneleyo ibekwe emgangathweni. Oogqirha botyando kulindeleke ukuba benze isampulu yezikhululo ezithile ezisekelwe kwindawo yethumba. Oku kungqongqo kuqinisekisa ukuhambelana kumaziko onke kwaye kuvumela ukuthelekiswa okungcono kweziphumo kulingo lwezonyango. Yintsika esisiseko yokhathalelo oluphezulu lotyando lwe-thoracic.

Ukukhethwa kwezigulane kunye noVavanyo lweZifundo ezininzi

Ayisiso sonke isigulana esingumgqatswa wonyango lwe-neo-adjuvant olulandelwa lutyando. Ukukhethwa kwezigulane ngokungqongqo kubaluleke kakhulu ukuqinisekisa ukhuseleko kunye nokusebenza kakuhle. Imvumelwano ka-2026 igxininisa indima ye-Multidisciplinary Team (MDT) ekuphononongeni zonke iimeko. Eli qela libandakanya oogqirha botyando lwesifuba, ii-oncologists zonyango, i-radiation oncologists, i-radiologists, kunye nee-pathologists.

Imiba ephambili ekukhetheni ibandakanya imeko yokusebenza, i-comorbidities, kunye ne-tumor biology. Izigulane ezinesimo esibi sokusebenza azikwazi ukunyamezela ukudibanisa unyango lwenkqubo kunye nokuhlinzwa okukhulu. Ngokufanayo, abo banokubandakanyeka ngokubanzi kwe-mediastinal okanye i-metastases ekude banokufuna izicwangciso ezahlukeneyo zokulawula. I-MDT iphonononga zonke iziphumo ze-imaging kunye ne-biopsy ukwenza isicwangciso somntu.

Uvavanyo lweBiomarker luyimfuneko yokuthatha isigqibo. Iprofayili ebanzi ye-genomic ichonga abaqhubi abafana ne-EGFR, i-KRAS, okanye i-HER2, ekhokela ukhetho lwee-arhente ekujoliswe kuzo. Amanqanaba enkcazo yePD-L1 anceda ukuqikelela amathuba okuphendula kwi-immunotherapy. Ngaphandle kwale mephu yendlela yemolekyuli, unyango luya kuba luncedo kwaye lungasebenzi kakuhle. Iyeza elichanekileyo liqala ngokuxilongwa ngokuchanekileyo.

Ukucwangciswa koMngcipheko kunye nokuPhuculwa kwangaphambili

Ngaphambi kokuba kuqaliswe unyango lwe-neo-adjuvant, izigulana ziphantsi komngcipheko ocacileyo. Oku kubandakanya ukuvavanya ukusebenza kwentliziyo, ukugcinwa kwemiphunga, kunye nesimo sesondlo. Iinkqubo zangaphambi kokubuyela kwimeko yesiqhelo ziya kucetyiswa ukuba ziphucule izigulane ngokwasemzimbeni phambi kokuba ziqale unyango. Ukuzivocavoca, ukuyeka ukutshaya, kunye nokuphuculwa kokutya kunokunciphisa kakhulu iingxaki emva kokuhlinzwa.

Ukuyeka ukutshaya kubaluleke kakhulu. Ukutshaya okuqhubekayo ngexesha lonyango lwe-neo-adjuvant kunokuphazamisa ukuphiliswa kwenxeba kunye nokwandisa umngcipheko wosulelo. Ngaphezu koko, ukutshaya kunokuphazamisana nokusebenza konyango oluthile. Izigulane zicetyiswa ngamandla ukuba ziyeke ngokukhawuleza xa zixilongwa ukuze zandise inzuzo yalo lonke uhambo lonyango.

Inkxaso yengqondo nayo iyinxalenye ephambili. Ithemba leendlela zonyango ezininzi kunokuba nzima. Amaqela eengcebiso kunye nenkxaso anceda izigulana ukuba zikwazi ukujongana nemingeni yeemvakalelo zoxilongo lwabo. Isigulana esilungiselelwe ngokwasengqondweni kunokwenzeka ukuba sibambelele kwimigaqo yonyango kwaye sichache ngokukhawuleza kuqhaqho.

Uhlalutyo lokuthelekisa lwe-Neo-Adjuvant Strategies

Ukuqonda umahluko phakathi kweendlela ezahlukeneyo ze-neo-adjuvant kunceda ekulungiseleleni unyango kwiimfuno zomntu ngamnye. Itheyibhile engezantsi ithelekisa amacebo aphambili asetyenziswayo ngoku utyando lonyango lomhlaza wemiphunga iiprothokholi.

Olu thelekiso lubonisa ukuba akukho sisombululo silinganayo. Ukhetho luxhomekeke kakhulu kwiprofayili ye-molecular ye-tumor kunye ne-physiological reserve yesigulane. I-Chemo-immunotherapy iye yaba yirejimeni ebalaseleyo yamathumba ohlobo lwasendle ngenxa yeempendulo eziphezulu ze-pathological. Nangona kunjalo, unyango olujoliswe kuyo luhlala luyimfuneko kubantu abaguqukileyo.

Unyango olusakhulayo lwe-triplet lubonisa isithembiso kulingo lwakwangoko kodwa alukabikho umgangatho wokhathalelo ngaphandle kophando lwezonyango. Ezi rejimeni zijolise ekutyhaleni imida yento enokufezekiswa, enokuthi iguqule nangakumbi iimeko ezinokuphinda ziphinde zibuyele emdeni. Njengoko idatha ikhula, olu khetho lunokwandisa izixhobo zokusebenza ezifumanekayo kwiiklinikhi.

Ukulawula Ubutyhefu kunye nexesha loTyando

Inkalo ebalulekileyo yokudibanisa unyango lwe-neo-adjuvant kunye utyando lonyango lomhlaza wemiphunga ilawula ubuthi. Unyango olucwangcisiweyo lunokubangela iziphumo ebezingalindelekanga ezichaphazela ukulungela utyando. Iziganeko ezimbi ezinxulumene ne-immune (irAEs) ezifana ne-pneumonitis okanye i-colitis kufuneka zichongwe kwaye zilawulwe ngokukhawuleza ukuphepha ukulibazisa utyando.

Ixesha liyinto yonke. Ikhefu phakathi kwethamo lokugqibela lonyango lwe-neo-adjuvant kunye notyando libalwa ngononophelo. Ngokuqhelekileyo, utyando lucwangciselwe i-3 kwiiveki ze-6 emva komjikelezo wokugqibela. Le festile ivumela ubuthi obubukhali ukusombulula ngelixa ugcina isiphumo sonyango. Ukusebenza kwakamsinya kakhulu kunokonyusa iingxaki, ngelixa ukulinda ixesha elide kunomngcipheko wokukhula kwakhona kwethumba.

Oogqirha botyando kufuneka baqaphele iimpawu zobuthathaka bezicubu okanye ukunamathela okungalindelekanga okubangelwa unyango lwangaphambili. Iziphumo zotyando zinokwahluka kumfanekiso waphambi kotyando. Ukuguquguquka kunye namava kuyafuneka ukulungelelanisa isicwangciso sotyando ngexesha langempela. Injongo kukuphumeza ukutshatyalaliswa ngokupheleleyo ngaphandle kokuphazamisa ukhuseleko lwesigulane.

I-Post-Operative Care kunye neZigqibo ze-Adjuvant

Uhambo alupheli ngotyando. Ukunyamekela emva kokusebenza kulungiselelwe ngokusekelwe kwimpendulo ye-pathological kwi-neo-adjuvant therapy. Izigulane ezifumana impendulo epheleleyo ye-pathological (pCR) ingaba neshedyuli eyahlukileyo yokulandelelana xa kuthelekiswa nalabo abanesifo esisele. Ubungakanani be-tumor eshiyekileyo bubungqina obunamandla bokuphindaphinda kwixesha elizayo.

Izigqibo zonyango lwe-Adjuvant ngoku zibaluleke kakhulu. Kwizigulane ezifumene i-neo-adjuvant immunotherapy kwaye zafumana impendulo efanelekileyo, ukuqhubeka kwe-immunotherapy emva kokusebenza kudla ngokucetyiswa ukuba kuhlanganiswe inzuzo. Le "sandwich" indlela yokwandisa ixesha lokuvezwa kwamajoni omzimba. Ngakolunye uhlangothi, ukuba ukuqhubela phambili kwenzeka ngexesha lonyango lwe-neo-adjuvant, ukutshintshela kudidi olwahlukileyo lwamachiza kuyimfuneko.

Iiprothokholi zokucupha nazo zihlaziyiwe. Ukucinga rhoqo kunye nokujongwa kwe-biomarker kubalulekile ukuze kubonwe iimpawu zokuphinda zivele kwangoko. Ukusetyenziswa kwe-liquid biopsies (ctDNA) ifumana ukuthandwa kakhulu ngokufumanisa ukuphinda kwemolekyuli phambi kokuba ibonakale kwizikena. Oku kuvumela ukungenelela kwangaphambili kunye neziphumo ezinokuba ngcono.

Izalathiso zexesha elizayo kunye nobuGcisa obusakhulayo

Ukujonga ngaphaya kwe2026, intsimi ye utyando lonyango lomhlaza wemiphunga iyaqhubeka nokuvela ngokukhawuleza. I-Artificial Intelligence (AI) iqala ukudlala indima ekuqikeleleni impendulo kwi-neo-adjuvant therapy. Ii-algorithms ezihlalutya iimpawu ze-radiomic ezivela kwi-CT scans zinokuqikelela ukuba zeziphi izigulane ezinokufikelela kwi-pCR, zinceda ekukhetheni unyango.

Iiklasi ezitsha zamachiza, ezifana ne-Antibody-Drug Conjugates (ADCs), zingena kwindawo ye-neo-adjuvant. Ezi molekyuli zihambisa ichemotherapy enamandla ngokuthe ngqo kwiiseli zomhlaza, zigcina izicubu ezisempilweni. Ulingo lwakwangoko lucebisa ukuba bangaba ngabatshintshi bomdlalo kwizigulana ezingaphenduliyo kwi-immunochemotherapy eqhelekileyo. Ukudityaniswa kwabo kumsebenzi wotyando kulindelwe kwiminyaka ezayo.

Ukongeza, ingcamango "yokugcinwa kwamalungu" iphononongwa ngamandla. Kwizigulane ezikhethiweyo ezineempendulo ezigqwesileyo, utyando oluncinci okanye nolawulo olungaphangeliyo lunokuqwalaselwa kwixesha elizayo. Ngelixa utyando luhlala lukumgangatho wegolide wonyango, inkcazo yonyango lonyango iyakhula ukuze iquke iindlela ezisebenza kakhulu ezingaphazamisiyo.

Impembelelo yemfuzo kuCwangciso loMzobo kuTyando

Iprofayile yemfuzo ebanzi iya isiba yisiqhelo phambi kwaso nasiphi na isigqibo sonyango. Ukuchonga imixube enqabileyo efana ne-NRG1 okanye i-MET amplifications ivula iingcango kunyango oluthile olujoliswe kuyo. Njengoko uluhlu lweethagethi ezinokuthathwa lukhula, i-algorithm yotyando iba nzima ngakumbi kodwa ichaneke ngakumbi. Oogqirha botyando kufuneka bahlale behlaziywa ngezinto zamva nje ezifunyenweyo zemolekyuli ukuze zinike olona nyango lubalaseleyo.

Ukudibana phakathi kofuzo kunye ne-immune microenvironment yenye indawo yophononongo olunzulu. Ukuqonda ukuba kutheni ezinye iithumba "zishushu" (i-immune-inflamed) kwaye ezinye "ziyabanda" kunceda ekuyileni iirejimeni ezingcono ze-neo-adjuvant. Ukuguqula amathumba abandayo abe ashushu phambi kotyando kunokuvula izibonelelo zonyango lwe-immunotherapy kuluntu olubanzi.

Ekugqibeleni, ikamva lilele kubuntu. Umhlaza wesigulana ngasinye wahlukile, kwaye kufuneka kube njalo indlela yabo yonyango. Ukudityaniswa koxilongo oluphucukileyo, unyango olunoveli, kunye neendlela zotyando ezisulungekileyo zithembisa ikamva apho umhlaza wemiphunga uye ulawuleka, kwaye uhlala unyangeka, imeko.

Imibuzo Ebuzwa Rhoqo malunga neNeo-Adjuvant Lung Cancer Care

Izigulane kunye neentsapho zihlala zinemibuzo emininzi xa zijongene noxilongo olubandakanya utyando lonyango lomhlaza wemiphunga. Ukujongana nezi nkxalabo kunceda ukunciphisa ixhala kunye nokuqinisekisa imvume enolwazi. Ngezantsi kukho iimpendulo kwimibuzo eqhelekileyo esekelwe kwimvumelwano yezonyango yangoku.

• Ngaba unyango lwe-neo-adjuvant lulibazisa utyando? Ngelixa yongeza ixesha ngaphambi kotyando, ukulibaziseka kwenziwa ngabom kwaye kunenzuzo. Ivumela i-tumor shrinkage kunye nokulawulwa kwenkqubo, ekugqibeleni iphucula impumelelo yotyando kunye nokuphila ixesha elide.
• Ngaba utyando lusenokwenzeka ukuba ithumba alincipha? Ewe, kwiimeko ezininzi. Kwanangaphandle kokucutheka okuphawulekayo, unyango lusenokuba lubulele izifo ezincinane kakhulu. Iqela lotyando liza kuphinda lihlolisise kwakhona ukubuyisela kwakhona ngokusekelwe kwi-imaging ehlaziyiweyo kunye nesimo seklinikhi.
• Zeziphi iziphumo ebezingalindelekanga zonyango lwangaphambi kotyando? Iziphumo ebezingalindelekanga ezixhaphakileyo ziquka ukudinwa, isicaphucaphu, kunye nemiba enxulumene nomzimba wokuzikhusela njengerhashalala okanye ukungasebenzi kakuhle kwe-thyroid. Uninzi luyalawuleka ngononophelo lwenkxaso kwaye aluthinteli utyando.
• Kuthatha ixesha elingakanani ukuchacha emva kotyando emva konyango lwe-neo-adjuvant? Amaxesha okuchacha ayahluka kodwa ngokubanzi ayafana notyando lodwa, ngakumbi ngobuchule obungephi. Iiprothokholi eziphuculweyo zokubuyisela kwakhona izigulane zibuyela kwimisebenzi yesiqhelo ngokukhawuleza.

Unxibelelwano oluvulelekileyo neqela lezempilo lubalulekile. Izigulane kufuneka zizive zixhotyisiwe ukuba zibuze malunga nengqiqo emva kwesicwangciso sazo sonyango. Ukuqonda iinjongo zonyango lwe-neo-adjuvant kukhuthaza ukuthembana kunye nentsebenziswano, eziyimfuneko ekujongeni ubunzima bokhathalelo lomhlaza.

Isiphelo: Ixesha elitsha leZigulana zoMhlaza weLung

Unyaka ka-2026 uphawula ixesha lenguqu utyando lonyango lomhlaza wemiphunga. Ukuhlanganiswa okungenamthungo kwe-neo-adjuvant immunotherapy kunye nee-arhente ezijoliswe kuzo ziwuphakamisile umgangatho wokhathalelo, zibonelela ngamathuba angazange abonwe ngaphambili okunyanga. Izigulana ezikhe zajongana nokhetho olulinganiselweyo ngoku zinokufikelela kwiindlela ezintsonkothileyo, iindlela ezininzi ezijongana nesifo sasekhaya kunye nesistim.

Intsebenziswano phakathi kwee-oncologists zonyango kunye noogqirha be-thoracic ayizange ibaluleke kakhulu. Ngokudibeneyo, bajonga ubunzima be-algorithms yonyango lwangoku ukuhambisa ukhathalelo lomntu. Njengoko uphando luqhubeka nokutyhila ulwazi olutsha kunye nonyango, ukuxilongwa kwezigulana zomhlaza wemiphunga kuyaqhubeka ukuphucuka ngokuthe ngcembe.

Nabani na ojongene nolu xilongo, umyalezo ucacile: ithemba liyinyani, kwaye inkqubela iyabambeka. Ngokudityaniswa okuchanekileyo kwenzululwazi ebukhali kunye nokhathalelo lotyando lobuchwephesha, ukoyisa umhlaza wemiphunga kufikeleleka ngakumbi kunangaphambili. Olu hambo lulucelomngeni, kodwa indawo ekusingwa kuyo—ubomi obungenawo umhlaza—ifikeleleka kubantu abaninzi.